May 28, 2008
PharmaIN and Pacific Northwest Diabetes Research Institute announce preclinical research collaboration to study new drug combination to treat diabetes
PharmaIN Corporation and Pacific Northwest Diabetes Research Institute (PNDRI) announced today that they are collaborating on a project to evaluate the benefit of combining PharmaIN’s long-acting formulation of native, human GLP-1 (PGC GLP-1) with sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor marketed by Merck under the brand name JANUVIA™.

Feb. 20, 2008
PharmaIN announces award from National Institutes of Health to formulate potential new therapy to treat serious staphylococcal infections including MRSA
The multi-year, $400,000 award from NIH will advance early stage development of the Company's novel formulation of an anti-infective drug to combat MRSA.
On February 20, 2008, PharmaIN Corporation announced that the Company received a Notice of Grant Award (NGA) from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) in support of the project "Nanocarrier with metal bridge for affinity based delivery of metal binding peptide." The grant award is for $400,000 over two years and will support the Company's research to develop a convenient, single administration therapy to treat infections caused by the bacteria called Staphylococcus aureus, especially targeting methicillin-resistant or vancomycin-resistant strains (commonly called MRSA and VRSA). This award also makes possible additional support for the project in the form of a $1.2MM phase 2 SBIR award.

Jun. 25, 2007
PharmaIN announces presentation of preclinical, type 1 diabetes data at 2007 Annual Scientific Sessions of the American Diabetes Association
Preclinical data suggests a long-acting formulation of native, human GLP-1 can promote the growth of insulin producing cells (beta cells) in a type 1 diabetes animal model.

Jun. 25, 2007
PharmaIN announces preclinical data on once weekly dosing, long-acting, natural GLP-1 formulation to treat type 2 diabetes
Preclinical data suggests native, human GLP-1 formulation can be dosed weekly and impact HbA1c levels dramatically in diabetic rat model of type 2 diabetes.

Apr. 23, 2007
PharmaIN announces $3 million award
from National Institute of Health
Significant award from NIH will advance Company's development of its novel therapy to treat type 1 diabetes.

Jan. 08, 2007
PharmaIN adds diabetes expert Riccardo Perfetti, MD, PhD
as new scientific advisor.
Experienced clinical and preclinical diabetes researcher to act in advisory role as Company plans clinical development for lead product, PGC GLP-1.

Jan. 04, 2007
PharmaIN receives first US patent for drug delivery technology.
First Company patent expands existing intellectual property estate with broad application toward improving pharmaceutical and biopharmaceutical products.